Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Campus
Campus

Management of Allergic Rhinitis Aggravated by Air Pollution

Pollution is the introduction of harmful substances, or pollutants, into the environment that leads to the deterioration of the quality of air, water, and land.

The impact of air pollution on allergic symptoms is modulated by 4 factors.

Air pollutants

A mixture of solid particles, liquid droplets and gases. Air pollutants can be natural, such as bush fires, or created by human activity, such as motor vehicles.

  

Allergens

Biological air pollutants derive from living organisms. Some allergens are more significant indoors, while others are more important outdoors.
Particulate matter Diesel Exhaust Particles (DEP) Ozone House dust mites Pet dander Pollen

Ultra-fine
(<1 μm)

Fine
(<1–2.5 μm)

Coarse
(2.5–10 μm)

 Outdoor air pollution constituted more than 3% of the annual Disability-Adjusted Life Year in 2010.      

Recommendations for patients

  • Avoidance

Remain indoors during high pollen levels.

  • Elimination

Eliminate sources of indoor mold spores, clean thoroughly.

  • Treatment

Recommend 2nd generation antihistamines or intranasal corticosteroids, anticholinergics, and nasal lavage

References

Naclerio R, Ansotegui IJ, Bousquet J et al. World Allergy Organ J. 2020 Mar; 13(3): 100106. Published online 2020 Apr 3. doi: 10.1016/j.waojou.2020.100106

How to create a healthy environment

References

  1. Naclerio R, Ansotegui IJ, Bousquet J et al. World Allergy Organ J. 2020 Mar; 13(3): 100106. Published online 2020 Apr 3. doi: 10.1016/j.waojou.2020.100106

Reference: Telfast® 180 mg film-coated tablets Patient Information leaflet ; Revision Date November 2020

Sanofi Consumer Health Care 87 Yarraman Place; Virginia QLD 4014, Australia.

Disclaimer:*Fexofenadine HCl 180 mg is registered in both markets of UAE and KSA please refer to the respective Patient Information leaflet.

 Consumer HealthCare Details:

Opella Healthcare International SAS
First Floor , Office 101, Building 25, Dubai Healthcare City, Dubai, United Arab Emirates
For further medical information, please contact the following: For UAE: 800 OPELLAAE (800 67355223) Direct Line (+971522163940)
For all Gulf Countries: CHCMedical-Information.ME@sanofi.com
To report adverse events, please call +971522164011 or contact Opella Country Safety Head at CHCPVME@sanofi.com
For UAE only you may also contact MOHAP PV department at: PV@mohap.gov.ae
To report any Product Technical Complaint please contact CHC.me.quality@sanofi.com

Related articles
MAT-AE-2300066/V1/Feb 2023